Targeting RTK-PI3K-mTOR Axis in Gliomas: An Update

Area of Science:

• Neuro-oncology
• Molecular Biology
• Pharmacology

Background:

• Gliomas are aggressive central nervous system (CNS) tumors known for infiltration, recurrence, and resistance to therapies.
• Current treatments, including surgery and radiation, offer limited efficacy, highlighting the need for novel therapeutic strategies.
• Tumor recurrence often coincides with acquired therapy resistance, necessitating well-tolerated drugs for durable patient responses.

Purpose of the Study:

• To investigate the therapeutic potential of targeting the RTK/PI3K/Akt/mTOR pathway in gliomas.
• To identify challenges and future directions for developing effective pharmacological approaches against glioma.

Main Methods:

• Review of molecular alterations in the RTK/PI3K/Akt/mTOR pathway in glioma.
• Analysis of clinical trial outcomes for drugs targeting this pathway.
• Discussion of factors limiting therapeutic efficacy, such as blood-brain barrier (BBB) penetration and resistance mechanisms.

Main Results:

• Aberrant signaling in the RTK/PI3K/Akt/mTOR pathway is a common feature of gliomas.
• Clinical trials targeting this pathway have yielded disappointing results due to poor BBB permeability and resistance.
• Despite challenges, the pathway's central role in cell growth and survival supports continued targeting strategies.

Conclusions:

• Targeting the RTK/PI3K/Akt/mTOR pathway remains a valid strategy for glioma treatment.
• Future research must address tumor heterogeneity, microenvironment interactions, and optimized dosing for improved efficacy and response prediction.
• Rigorous clinical studies are essential to overcome current limitations and realize the therapeutic potential of RTK/PI3K/Akt/mTOR inhibitors in gliomas.